Floatz logo

37 assets in Bladder Transitional Cell Carcinoma

Therapeutic assets addressing Bladder Transitional Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
Bladder Transitional Cell Carcinoma
Nagoya UniversityP3BB (70)
Atezolizumab
Bladder Transitional Cell Carcinoma
KaliVir ImmunotherapeuticsP3BB (68)
Carboplatin
Bladder Transitional Cell Carcinoma
Jonsson Comprehensive Cancer CenterP2BB (67)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Bladder Transitional Cell Carcinoma
Fred Hutchinson Cancer CenterP2BB (65)
Nivolumab
Bladder Transitional Cell Carcinoma
Nagoya UniversityP3BB (65)
Pembrolizumab
Bladder Transitional Cell Carcinoma
Fred Hutchinson Cancer CenterP3BB (65)
Durvalumab
Bladder Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3B (63)
Cyclophosphamide
Bladder Transitional Cell Carcinoma
Hadassah Medical OrganizationP2B (60)
Fludarabine
Bladder Transitional Cell Carcinoma
Hadassah Medical OrganizationP2B (59)
Ipilimumab
Bladder Transitional Cell Carcinoma
M.D. Anderson Cancer CenterP2B (59)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Bladder Transitional Cell Carcinoma
National Cancer Institute (NCI)P2B (58)
Avelumab
Bladder Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3B (57)
9mw2821
Bladder Transitional Cell Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd.P2CCC (53)
Apsolol
Bladder Transitional Cell Carcinoma
Emory UniversityP2CCC (53)
Eribulin Monomethanesulfonate
Bladder Transitional Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Rain-32
Bladder Transitional Cell Carcinoma
Rain Oncology IncP2CCC (53)
Relatlimab
Bladder Transitional Cell Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Tamivarotene
Bladder Transitional Cell Carcinoma
Nagoya UniversityP2CCC (53)
Tocilizumab
Bladder Transitional Cell Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Toripalimab
Bladder Transitional Cell Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd.P2CCC (53)
Hbi 0201-Eso Tcrt
Bladder Transitional Cell Carcinoma
Hadassah Medical OrganizationP1/2CCC (48)
Rifaximin
Bladder Transitional Cell Carcinoma
Mansoura UniversityP1/2CCC (48)
Cdx-585
Bladder Transitional Cell Carcinoma
Celldex TherapeuticsP1CC (47)
Quemliclustat
Bladder Transitional Cell Carcinoma
Fred Hutchinson Cancer CenterP1/2CC (47)
Cabozantinib
Bladder Transitional Cell Carcinoma
National Cancer Institute (NCI)P1CC (43)
Docetaxel
Bladder Transitional Cell Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Etoposide
Bladder Transitional Cell Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
hc-7366
Bladder Transitional Cell Carcinoma
HiberCell, Inc.P1CC (43)
ngm438
Bladder Transitional Cell Carcinoma
NGM Biopharmaceuticals, IncP1CC (43)
ngm831
Bladder Transitional Cell Carcinoma
NGM Biopharmaceuticals, IncP1CC (43)
[225Ac]Ac-AKY-1189
Bladder Transitional Cell Carcinoma
Aktis Oncology, Inc.P1CC (41)
[64Cu]Cu-AKY-1189
Bladder Transitional Cell Carcinoma
Aktis Oncology, Inc.P1CC (41)
Bl-M17D1
Bladder Transitional Cell Carcinoma
SystImmune Inc.P1CC (41)
Rndo-564
Bladder Transitional Cell Carcinoma
Rondo TherapeuticsP1CC (41)
vet3-tgi
Bladder Transitional Cell Carcinoma
KaliVir ImmunotherapeuticsP1CC (41)
Milademetan
Bladder Transitional Cell Carcinoma
Rain Oncology IncP1/2C (33)
an0025
Bladder Transitional Cell Carcinoma
Adlai Nortye Biopharma Co., Ltd.P1NR ()